timeline

Also in 2017

2018-09-07T15:57:09+09:30February 7th, 2017|timeline|

Also in 2017, the FDA approved for use two CAR-T cell therapies to treat children and young adults with ALL and adults with diffuse large B-cell lymphoma.

In 2017

2018-09-07T15:57:49+09:30February 7th, 2017|timeline|

In 2017 CAR-T therapy was named Advance of the Year by the American Society for Clinical Oncology.

Third-generation CARs

2018-09-07T15:59:42+09:30September 7th, 2015|timeline|

Third-generation CAR molecules were produced by incorporating two or more co-stimulatory molecules into the CAR construct. These CARs are not necessarily more superior than second-generation (results from comparative studies are

In 2014

2018-09-07T16:02:29+09:30September 7th, 2014|timeline|

In 2014 CAR-T therapy received Breakthrough Drug designation from the US Food and Drug Administration for relapsed and/or refractory acute lymphoblastic leukaemia.

Late 1990s …

2018-09-07T16:09:39+09:30September 7th, 1998|timeline|

In the late 1990s it was found that CARs would be more effective if they were designed with the addition of another molecule - a ‘co-stimulatory’ molecule to work alongside of

Early 1980s …

2018-09-07T16:06:03+09:30September 7th, 1982|timeline|

Studies in the early 1980s demonstrated that intravenous injection of T cells expanded in IL-2 could treat bulky subcutaneous lymphomas, and the administration of IL-2 after cell transfer increased T